CD45 has been shown to be functionally important in murine models of Alzheimer’s disease (49), and microglial CD45 may be a potential therapeutic target in inflammatory CNS diseases, as has been proposed for systemic immunological and neoplastic diseases (23). Here, PTPRC is linked to early-onset autosomal dominant Alzheimer disease.